Oral pharmacokinetics of omeprazole

Colin Howden, P. A. Meredith, J. A.H. Forrest, J. L. Reid

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of omeprazole from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound.

Original languageEnglish (US)
Pages (from-to)641-643
Number of pages3
JournalEuropean Journal of Clinical Pharmacology
Volume26
Issue number5
DOIs
StatePublished - Sep 1 1984
Externally publishedYes

Fingerprint

Omeprazole
Pharmacokinetics
Gastric Acid
Area Under Curve
Healthy Volunteers
Acids

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Howden, C., Meredith, P. A., Forrest, J. A. H., & Reid, J. L. (1984). Oral pharmacokinetics of omeprazole. European Journal of Clinical Pharmacology, 26(5), 641-643. https://doi.org/10.1007/BF00543502

Oral pharmacokinetics of omeprazole. / Howden, Colin; Meredith, P. A.; Forrest, J. A.H.; Reid, J. L.

In: European Journal of Clinical Pharmacology, Vol. 26, No. 5, 01.09.1984, p. 641-643.

Research output: Contribution to journalArticle

Howden, C, Meredith, PA, Forrest, JAH & Reid, JL 1984, 'Oral pharmacokinetics of omeprazole', European Journal of Clinical Pharmacology, vol. 26, no. 5, pp. 641-643. https://doi.org/10.1007/BF00543502
Howden, Colin ; Meredith, P. A. ; Forrest, J. A.H. ; Reid, J. L. / Oral pharmacokinetics of omeprazole. In: European Journal of Clinical Pharmacology. 1984 ; Vol. 26, No. 5. pp. 641-643.
@article{17e17f7cae6a402b953e32df64a18178,
title = "Oral pharmacokinetics of omeprazole",
abstract = "The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of omeprazole from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound.",
author = "Colin Howden and Meredith, {P. A.} and Forrest, {J. A.H.} and Reid, {J. L.}",
year = "1984",
month = "9",
day = "1",
doi = "10.1007/BF00543502",
language = "English (US)",
volume = "26",
pages = "641--643",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Oral pharmacokinetics of omeprazole

AU - Howden, Colin

AU - Meredith, P. A.

AU - Forrest, J. A.H.

AU - Reid, J. L.

PY - 1984/9/1

Y1 - 1984/9/1

N2 - The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of omeprazole from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound.

AB - The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of omeprazole from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound.

UR - http://www.scopus.com/inward/record.url?scp=0021272130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021272130&partnerID=8YFLogxK

U2 - 10.1007/BF00543502

DO - 10.1007/BF00543502

M3 - Article

C2 - 6468483

AN - SCOPUS:0021272130

VL - 26

SP - 641

EP - 643

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 5

ER -